Clover Health Investments (CLOV) Expected to Announce Earnings on Thursday

Clover Health Investments (NASDAQ:CLOV) is expected to announce its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.05) per share and revenue of $467.0560 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 26, 2026 at 5:00 PM ET.

Clover Health Investments Stock Performance

NASDAQ CLOV opened at $2.09 on Thursday. Clover Health Investments has a one year low of $2.01 and a one year high of $4.80. The stock has a 50-day moving average of $2.42 and a 200 day moving average of $2.65. The company has a market capitalization of $1.08 billion, a price-to-earnings ratio of -19.00 and a beta of 2.09.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on CLOV shares. Canaccord Genuity Group reissued a “buy” rating and set a $3.70 price objective on shares of Clover Health Investments in a report on Tuesday, January 20th. Zacks Research lowered shares of Clover Health Investments from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Clover Health Investments in a report on Monday, December 29th. Finally, Wall Street Zen raised Clover Health Investments from a “sell” rating to a “hold” rating in a report on Sunday. One analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Clover Health Investments has an average rating of “Hold” and an average target price of $3.23.

Hedge Funds Weigh In On Clover Health Investments

Several institutional investors and hedge funds have recently bought and sold shares of CLOV. AQR Capital Management LLC purchased a new stake in Clover Health Investments in the first quarter worth about $49,000. Integrated Wealth Concepts LLC bought a new position in shares of Clover Health Investments during the 1st quarter valued at approximately $37,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Clover Health Investments by 3.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 855,264 shares of the company’s stock valued at $3,070,000 after acquiring an additional 24,807 shares during the period. Envestnet Asset Management Inc. purchased a new stake in Clover Health Investments in the 2nd quarter worth approximately $31,000. Finally, JPMorgan Chase & Co. raised its stake in Clover Health Investments by 41.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 633,700 shares of the company’s stock worth $1,768,000 after acquiring an additional 186,047 shares during the period. 19.77% of the stock is currently owned by hedge funds and other institutional investors.

Clover Health Investments Company Profile

Clover Health Investments is a technology-driven healthcare company specializing in Medicare Advantage plans for senior populations. The company combines insurance coverage with a proprietary software platform to improve care coordination, outcomes tracking and cost management. By leveraging data analytics, Clover Health aims to deliver personalized care pathways and preventive interventions for its members.

At the core of Clover’s offering is its Clover Assistant platform, which aggregates clinical and claims data from multiple sources to create real-time insights for physicians and care teams.